Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The cell binding domain of type I collagen is a specific peptide sequence within the larger type I collagen protein that mediates binding to cell-surface receptors, mainly integrins (e.g., α2β1) and fibronectin. These domains include motifs adjacent to the matrix metalloprotease-1 (MMP-1) cleavage site and other sites within the triple-helical region of collagen, often characterized by Gly-X-Y repeat motifs such as GFOGER or GLOGER. These regions facilitate cell adhesion, trigger intracellular signaling, and coordinate extracellular matrix remodeling essential for tissue homeostasis and development. The cell binding domain is instrumental in physiological processes like wound healing and pathological states, including cancer invasion and tissue fibrosis, but is not a discrete pharmacological target itself.
Not applicable as a standalone therapeutic target, but the mechanism for blockers is disruption of collagen–integrin or collagen–fibronectin interactions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Cell binding domain of type I collagen.